Drug
Dalcetrapib clinical trials
- studies test it
- 17
- open now
- 1
- in phase 3
- 6
- first study started
- 2000
Keep track of what changes. Save the dalcetrapib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Hoffmann-La Roche (10) · DalCor Pharmaceuticals (3) · Akros Pharma Inc. (3) · Japan Tobacco Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dalcetrapib is read from its arms, and is right about nine times in ten.
Testing it · 17
- Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACSRecruitingPhase 3DalCor PharmaceuticalsNCT05918861Written as Dalcetrapib
- Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19CompletedPhase 2DalCor PharmaceuticalsNCT04676867Written as Dalcetrapib
- Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACSCompletedPhase 3DalCor PharmaceuticalsNCT02525939Written as dalcetrapib
- A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery DiseaseTerminatedPhase 3Hoffmann-La RocheNCT01059682Written as Dalcetrapib
- A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.CompletedPhase 2Hoffmann-La RocheNCT00353522Written as dalcetrapib
- A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart DiseaseCompletedPhase 2Hoffmann-La RocheNCT00655473Written as Dalcetrapib (RO4607381)
- A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381CompletedPhase 2Hoffmann-La RocheNCT00400439Written as dalcetrapib (RO4607381)
- A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary SyndromeCompletedPhase 3Hoffmann-La RocheNCT00658515Written as Dalcetrapib (RO4607381)
- A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent PatientsCompletedPhase 2Hoffmann-La RocheNCT00655538Written as dalcetrapib
- A Study of the Metabolic Profile of Dalcetrapib in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01476267Written as dalcetrapib
- A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01363999Written as dalcetrapib
- A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)CompletedPhase 3Hoffmann-La RocheNCT01323153Written as dalcetrapib
- A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular DiseaseCompletedPhase 3Hoffmann-La RocheNCT01516541Written as dalcetrapib
- Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) LevelsCompletedPhase 2Akros Pharma Inc.NCT00688558Written as JTT-705 600 mg and simvastatin 40 mg
- Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II HyperlipidemiaCompletedPhase 2Akros Pharma Inc.NCT00688896Written as JTT-705 600 mg and pravastatin 40 mg
- Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) LevelsCompletedPhase 2Akros Pharma Inc.NCT00689442Written as JTT-705 600 mg and atorvastatin 20 mg
- Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II HyperlipidaemiaCompletedPhase 2Japan Tobacco Inc.NCT00686010Written as JTT-705 300mg
Given in every arm · 1 — dalcetrapib is usual care beside what is tested
Codes
What other systems call dalcetrapib · ClinicalTrials.gg INT004257
- MeSH (NLM) C411602dalcetrapibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3D050LIQ3HDALCETRAPIBConfirmed FDA, NLM, Wikidata
- Wikidata Q5210285dalcetrapibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81529DalcetrapibOne source FDA
- DrugBank DB12181One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C411602 | dalcetrapib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3D050LIQ3H | DALCETRAPIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5210285 | dalcetrapib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81529 | Dalcetrapib | One source FDA |
| DrugBank | DB12181 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.